-
1 month ago | 
ophthalmologytimes.com | Sheryl Stevenson |Peter McDonnell |Nicole Bajic |John Berdahl |David Eichenbaum |Ehsan Sadri | +2 more
Half a decade after COVID-19 reshaped the landscape of health care, ophthalmology practices are still adapting—not out of crisis, but through continuous innovation and resilience. A key consideration now is which adaptations have endured, and which have been left behind. Understanding how patient behavior and expectations have shifted in this post-COVID landscape remains essential, prompting ongoing refinements in care delivery and operational strategy.
-
1 month ago | 
ophthalmologytimes.com | Sheryl Stevenson |Peter McDonnell |Nicole Bajic |John Berdahl |David Eichenbaum |Ehsan Sadri | +2 more
Five years ago, in April 2020, ophthalmologists across the country were navigating shuttered offices, improvised personal protective equipment (PPE), and a cascade of unknowns. Just weeks earlier, the World Health Organization had declared COVID-19 a global pandemic—setting in motion a series of events that would redefine clinical care. Now, in April 2025, we mark 5 years since that turning point—not just to remember the disruption, but to reflect on the transformation.
-
Nov 5, 2024 | 
healio.com | David Eichenbaum |Anthony DeFino |Christine Klimanskis
Read more You've successfully added Retina/Vitreous in Ophthalmology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this Healio Video Perspective from the Retina Society meeting, David A.
-
Oct 24, 2024 | 
healio.com | David Eichenbaum |Anthony DeFino |Christine Klimanskis
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. CHICAGO — In this Healio Video Perspective from the AAO meeting, David A. Eichenbaum, MD, discusses results from a phase 1 trial investigating axitinib for the treatment of neovascular age-related macular degeneration.
-
Oct 3, 2024 | 
healio.com | David Eichenbaum |Anthony DeFino |Christine Klimanskis
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this Healio Video Perspective from the Retina Society meeting, David A. Eichenbaum, MD, ofRetina Vitreous Associates of Florida, presents promising 12-month results from the DAVIO 2 trial.
-
Oct 1, 2024 | 
retinalphysician.com | David Eichenbaum
David A. Eichenbaum, MD, FASRS is director of research at Retina Vitreous Associates of Florida and collaborative associate professor at Morsani College of Medicine, University of South Florida, in Tampa, Florida. He has been a clinical trial investigator for the past 16 years, participating in more than 90 trials studying common retinal diseases such as dry and wet age-related macular degeneration, diabetic eye disease, and retinal vascular disease.
-
Jun 11, 2024 | 
healio.com | David Eichenbaum |Eamon Dreisbach |David Mullin |Christine Klimanskis
You've successfully added Retina/Vitreous in Ophthalmology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David A. Eichenbaum, MD, presents real-world data related to the use of aflibercept 8 mg.
-
May 31, 2024 | 
retinalphysician.com | Priya Sharma Vakharia |David Eichenbaum
Intravitreal injection therapy of anti‒vascular endothelial growth factor (anti-VEGF) continues to be one of the most effective and common procedures performed by vitreoretinal specialists.
-
May 15, 2024 | 
europe.ophthalmologytimes.com | Lynda Charters |David Eichenbaum
Ocular gene therapy is not yet ready for prime time, according to David Eichenbaum, MD. Eichenbaum is the director of research at Retina Vitreous Associates of Florida and a volunteer collaborative associate professor at USF Health Morsani College of Medicine in Tampa, Florida. He discussed the status of gene therapy technologies at the Hawaiian Eye and Retina 2024 meeting, held January 13 to 19 in Maui, Hawaii. “We are still in the infancy of gene therapy,” he said.
-
May 11, 2024 | 
healio.com | David Eichenbaum |Alex Young |Eamon Dreisbach
You've successfully added Retina/Vitreous in Ophthalmology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, David A.
